---
schema_version: "secwatch.filing_event.v1"
accession: "0001321732-24-000023"
form_type: "8-K"
ticker: "PEN"
cik: "0001321732"
company_name: "Penumbra Inc"
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T18:38:06.339451+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Penumbra Q4 revenue $284.7M (+28.7%); thrombectomy sales up 42.4%

## Summary
- Revenue of $284.7M in Q4 2023, up 28.7% YoY; full-year $1,058.5M, up 25.0%.
- Thrombectomy product revenue $190.8M in Q4 (+42.4%); full-year $677.3M (+32.5%).
- Net income $54.2M in Q4; adjusted EBITDA margin 18.8%; cash and investments up $40.3M.
- FY 2024 guidance: total revenue growth 16-20%, US thrombectomy growth 27-30%, gross margin +100-150bps.
- Non-GAAP operating income $37.4M in Q4; full-year $101.3M.

## SEC filing metadata
- accession: 0001321732-24-000023
- form_type: 8-K
- ticker: PEN
- cik: 0001321732
- company_name: Penumbra Inc
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321732/000132173224000023/0001321732-24-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321732/000132173224000023/pen-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001321732-24-000023
- JSON: https://secwatch.observer/filing/0001321732-24-000023.json
- Plain text: https://secwatch.observer/filing/0001321732-24-000023.txt

## Key facts
- Earnings Releases
  Penumbra Inc reported the fourth quarter and full year ended December 31, 2023 results: revenue $284.7 million, net income $54.2 million. Guidance reaffirmed.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: $284.7 million
  - Net income: $54.2 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: • Revenue of $284.7 million for the fourth quarter of 2023, an increase of 28.7% or 27.9% in constant currency 1 compared to the fourth quarter of 2022. Revenue of $1,058.5 million for the full year 2023,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321732/000132173224000023/0001321732-24-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.